Cargando…

A Combination of Gamma-Aminobutyric Acid, Glutamic Acid, Calcium, Thiamine, Pyridoxine, and Cyanocobalamin vs Ginger Extract in the Management of Chronic Motion Sickness: A Clinical Evaluation

BACKGROUND: Motion sickness (kinetosis) is a common and temporarily incapacitant ailment, manageable with behavioral as well as pharmacological measures. OBJECTIVE: To assess the effectiveness and safety of a combination of gamma-aminobutyric acid, glutamic acid, calcium, thiamine, pyridoxine, and c...

Descripción completa

Detalles Bibliográficos
Autores principales: Nunes, Carlos P., Rodrigues, Claudio, Suchmacher, Mendel, Esteves, Claudia Regina, Gonçalves, Karin, Rzetelna, Hélio, Rodrigues, Rafael V., de Vasconcelos, Luciana Regina, Mezitis, Spyros G.E., Rabelo, Heros, Kaufmann, Renato, Schwarz, Fernanda, Goldberg, Henrique, Sintoveter, Aline, Geller, Mauro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630771/
https://www.ncbi.nlm.nih.gov/pubmed/38021267
http://dx.doi.org/10.1016/j.curtheres.2023.100719
Descripción
Sumario:BACKGROUND: Motion sickness (kinetosis) is a common and temporarily incapacitant ailment, manageable with behavioral as well as pharmacological measures. OBJECTIVE: To assess the effectiveness and safety of a combination of gamma-aminobutyric acid, glutamic acid, calcium, thiamine, pyridoxine, and cyanocobalamin (Group A) (n = 170) and extract of Zingiber officinale (ginger) (Group B) (n = 165) in the management of chronic complaints consistent with motion sickness. METHODS: Both groups were tested according to the following end points, under self-paired as well as comparative study designs: reduction of ≥20 score points in the total motion sickness assessment questionnaire (MSAQ) score, percentage of patients presenting a reduction of the total MSAQ score, absolute MSAQ score reduction, physician's assessment scores, final overall assessment of study medication, and willingness to continue treatment. Safety was also evaluated. RESULTS: There was a statistically significant better performance under both study designs for Group A (P = 0.05 using different statistical tests) in all end points. Both regimens were safe, with different neurological and gastrointestinal tolerability outcomes. CONCLUSIONS: Group A and Group B regimens were effective and safe in the management of chronic complaints consistent with motion sickness and the Group A regimen was more effective than Group B.